āshibio raises $40 million in seed and Series A funding to advance bone and connective tissue disease therapies
– The first clinical program focuses on fibrodysplasia ossificans progressiva (FOP), a rare genetic disease that leads to extraskeletal bone formation – – Experienced leadership...